| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 6-K |
| 16 Nov 2026 | 6-K |
| 16 Nov 2026 | 6-K |
| 16 Nov 2026 | 6-K |
| 02 Nov 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 02 Nov 2026 | TOTAL VOTING RIGHTS |
| 30 Oct 2026 | 3RD QUARTER RESULTS |
| 27 Oct 2026 | ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC |
| 22 Oct 2026 | ULTOMIRIS APPROVED IN US IN IGAN |
| 05 Oct 2026 | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT |
| 02 Oct 2026 | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY |
| 01 Oct 2026 | ADMISSION OF FURTHER SECURITIES TO TRADING |
| 01 Oct 2026 | TOTAL VOTING RIGHTS |
| 29 Sep 2026 | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT |
| 23 Sep 2026 | TRIXEO APPROVED IN EU FOR ASTHMA |
| 21 Sep 2026 | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP |
| 21 Sep 2026 | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC |
| 18 Sep 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 15 Sep 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 15 Sep 2026 | DIRECTOR/PDMR SHAREHOLDING |
Loading...